Novo Nordisk (NYSE:NVO) is planning to distribute its weight-loss medications through the telehealth platform operated by ...

March 9 (Reuters) - Hims & Hers' shares were up over 50% in premarket trading on Monday following reports Novo Nordisk plans ...

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is seeking to recover damages.

Hims & Hers (HIMS) stock soared 44% premarket on news of a partnership with Novo Nordisk to sell weight-loss drugs, ending their legal feud.

Novo's lawsuit comes less than one week after Hims & Hers announced plans to sell a compounded version of Novo's weight-loss pill Wegovy.

Novo Nordisk has sued Hims & Hers for patent infringement, saying the online site is selling cheaper, unapproved copies of the Wegovy weight loss drug ...

Hims & Hers stock surged over 44% in premarket trading after a report said Novo Nordisk plans to sell its obesity drugs ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of ...

Add Yahoo as a preferred source to see more of our stories on Google. Novo Nordisk files suit against telehealth provider Hims & Hers, alleging unauthorized versions of Ozempic and Wegovy. The case ...

Novo Nordisk (NVO) stock is in focus as Strive Pharmacy, a pharmacy partner for Hims & Hers (HIMS) plans to offer a compounded version of Wegovy pill. Read more here.

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk ...

Novo Nordisk is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker's new Wegovy obesity pill and injections in the U.S. Novo is asking the ...